Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024GlobeNewswireMay 02, 2024GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Company Contact:Richard Eisenstadt Chief Financial Officer Phone: 240-654-1450 reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.comJulia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
COMTEX_451770641/2010/2024-05-02T07:30:32
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Company Contact:Richard Eisenstadt Chief Financial Officer Phone: 240-654-1450 reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.comJulia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
COMTEX_451770641/2010/2024-05-02T07:30:32
1.53% $0.11
